NCT02722538View on ClinicalTrials.gov

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 2, 2019

Study Completion Date

May 2, 2019

Conditions
Urinary Bladder Cancer
Interventions
DRUG

Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.

Trial Locations (6)

10032

Columbia University Medical Center, New York

Unknown

University of Southern California Norris Comprehensive Cancer Center, Los Angeles

University of Chicago Medical Center, Chicago

Johns Hopkins Hospital, Baltimore

Ohio State University Wexner Medical Center, Columbus

Radboudumc, Nijmegen

All Listed Sponsors
lead

Taris Biomedical LLC

INDUSTRY

NCT02722538 - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter